Chargement en cours...
Dasatinib in chronic myeloid leukemia: a review
Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic myeloid leukemia (CML), which provides an identifiable target for developing therapeutic agents. Imatinib mesylate, a BCR-ABL TK inhibitor, is the frontline therapy for CML. Despite the stunning efficacy of this ag...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2697539/ https://ncbi.nlm.nih.gov/pubmed/19536317 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|